NASDAQ:GRCE Grace Therapeutics (GRCE) Stock Price, News & Analysis $2.08 +0.01 (+0.48%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$2.08 0.00 (-0.24%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Grace Therapeutics Stock (NASDAQ:GRCE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Grace Therapeutics alerts:Sign Up Key Stats Today's Range$2.03▼$2.1750-Day Range$2.07▼$2.6952-Week Range$1.79▼$5.18Volume177,500 shsAverage Volume224,611 shsMarket Capitalization$33.84 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Grace Therapeutics, Inc. (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease. The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions. Through in-house capabilities and strategic partnerships with academic institutions and contract research organizations, Grace Therapeutics advances its candidates from target identification through lead optimization with the goal of accelerating entry into formal regulatory pathways. Based in the United States, Grace Therapeutics serves a global patient community by collaborating with development partners worldwide. The management team combines experience in drug discovery, clinical development and regulatory affairs, positioning the company to navigate the complex requirements of orphan drug designation and clinical trial execution. With a focus on innovation and strategic alliances, Grace Therapeutics aims to deliver transformative treatments for patients affected by rare genetic disorders.AI Generated. May Contain Errors. Read More Grace Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreGRCE MarketRank™: Grace Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 720th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingGrace Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialGrace Therapeutics has a consensus price target of $6.00, representing about 188.5% upside from its current price of $2.08.Amount of Analyst CoverageGrace Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Grace Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Grace Therapeutics is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Grace Therapeutics is -4.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGrace Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grace Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.28% of the float of Grace Therapeutics has been sold short.Short Interest Ratio / Days to CoverGrace Therapeutics has a short interest ratio ("days to cover") of 9.16.Change versus previous monthShort interest in Grace Therapeutics has recently decreased by 4.32%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGrace Therapeutics does not currently pay a dividend.Dividend GrowthGrace Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.92 News SentimentGrace Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Grace Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for GRCE on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grace Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.10% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions6.08% of the stock of Grace Therapeutics is held by institutions.Read more about Grace Therapeutics' insider trading history. Receive GRCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRCE Stock News HeadlinesGrace Therapeutics (NASDAQ:GRCE) Downgraded by Wall Street Zen to Sell3 hours ago | americanbankingnews.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationJuly 29 at 12:54 AM | finanznachrichten.deLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug AdministrationJuly 28, 2026 | globenewswire.comGrace Therapeutics (NASDAQ:GRCE) Stock Price Down 2.5% - Here's What HappenedJuly 23, 2026 | americanbankingnews.comGrace Therapeutics Inc Ordinary Shares GRCEJune 24, 2026 | morningstar.comMGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business UpdateJune 18, 2026 | globenewswire.comGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 11, 2026 | prnewswire.comSee More Headlines GRCE Stock Analysis - Frequently Asked Questions How have GRCE shares performed this year? Grace Therapeutics' stock was trading at $3.46 on January 1st, 2026. Since then, GRCE stock has decreased by 39.9% and is now trading at $2.08. How were Grace Therapeutics' earnings last quarter? Grace Therapeutics, Inc. (NASDAQ:GRCE) released its earnings results on Thursday, June, 18th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.17. How do I buy shares of Grace Therapeutics? Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/18/2026Today7/31/2026Next Earnings (Estimated)8/11/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 GRCE's financial health is in the Red zone, according to TradeSmith. GRCE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GRCE Previous SymbolNASDAQ:GRCE CIK1444192 Webwww.acastipharma.com Phone818-839-4378Fax45-0687-2272EmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Grace Therapeutics$6.00 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+188.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-14.45% Return on Assets-13.58% Debt Debt-to-Equity RatioN/A Current Ratio8.10 Quick Ratio8.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.50Miscellaneous Outstanding Shares16,270,000Free Float14,468,000Market Cap$33.84 million OptionableN/A Beta0.37 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:GRCE) was last updated on 8/1/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
